Therapeutic Response

ER positive and HER2-negative status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description
Faslodex (fulvestrant) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.
Faslodex (fulvestrant) [product monograph]. HC. Health Canada approved fulvestrant for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.